Peptides after menopause

Can you take peptides while on HRT (menopausal hormone therapy)?

It depends on the peptide and on your estrogen route. GLP-1 drugs have the most data: retrospective Mayo Clinic studies link HRT with somewhat greater weight loss on semaglutide, but none was randomized. Oral estrogen suppresses IGF-1, which may matter for GH-releasing peptides. PT-141, kisspeptin and topical GHK-Cu have no combination studies, so tell your prescriber everything you take.

Medically reviewedRead →

What's the best skincare protocol for menopausal skin thinning and collagen loss?

Estrogen loss drives ~30% collagen decline in the first five years post-menopause, plus dermal-epidermal junction flattening, hyaluronic-acid depletion, and reduced sebum. Standard anti-aging skincare under-performs because it targets cell turnover, not structure. Topical peptides (GHK-Cu 2–3% twice daily, Matrixyl 3000) plus mineral SPF outperform retinoid monotherapy — visible results at weeks 9–12.

Medically reviewedRead →

Do GLP-1s work for menopause weight gain, and what's different for women?

Yes. Semaglutide and tirzepatide produce large weight loss in peri- and postmenopausal women, and women lose more on average than men. The trade-off after menopause is bone and muscle: about a quarter of weight lost is lean tissue, and the Wegovy label reports more hip and pelvic fractures in women. Hormone-therapy benefits are observational only.

Medically reviewedRead →

Which peptides actually help women with low libido or sexual dysfunction, and what's the evidence?

PT-141 (Vyleesi) is FDA-approved for premenopausal HSDD — the only sexual-health peptide with female-specific approval. Kisspeptin shows promising early human evidence for female desire. Oxytocin has mixed data. The female sexual-health peptide space is actually better-evidenced than the male space because PT-141's approval was for women.

Medically reviewedRead →

Will kisspeptin and other emerging peptides actually help female sexual health, and when?

Yes — eventually. Kisspeptin targets the upstream hypothalamic GnRH/sexual-arousal circuit, distinct from PT-141 (dopaminergic) and flibanserin (serotonergic). Phase 2 data shows brain-activation and subjective response improvements, including in postmenopausal women. Not currently a clinical option. Realistic availability 2027-2030. Today's options remain PT-141, flibanserin, off-label testosterone, oxytocin.

Medically reviewedRead →

Are there peptides for osteoporosis or bone density after menopause?

Yes, but only prescription peptides have fracture data. Teriparatide and abaloparatide cut new spine fractures by roughly two-thirds or more in large trials. MOTS-c and BPC-157 have animal data only, despite a July 2026 FDA advisory vote on MOTS-c. Oral collagen showed small gains in one trial.

Medically reviewedRead →